Evidence map›Paper›PMID 29151974›Full record

ArticleJournal of Cancer2017

Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis.

Zhao-Ru Dong, Jie Zou, Dong Sun, Guo-Ming Shi, Ai-Wu Ke, Jia-Bin Cai, Hui-Chuan Sun, Shuang-Jian Qiu, Tao Li, Jian Zhou and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. [Value of ALBI grade on precised estimation liver reserve function of patients with hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Zhao-Ru DongLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jie ZouDepartment of Geriatrics, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
Dong SunDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, China.
Guo-Ming ShiLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ai-Wu KeLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jia-Bin CaiLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Hui-Chuan SunLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Shuang-Jian QiuLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Tao LiDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, China.
Jian ZhouLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xu-Ting ZhiDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, China.
Jia FanLiver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Fudan University · CNQilu Hospital of Shandong University · CNSun Yat-sen University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection remains the initial treatment of choice for the majority of early stage hepatocellular carcinoma (HCC) patients. Although the factors that influence the prognosis of postoperative HCC patients have been well elucidated, there are a limited number of simple, objective, and distinct methods for estimating survival for postoperative patients with solitary HCC within the Milan criteria and Child-Pugh (C-P) A cirrhosis. The Albumin-Bilirubin (ALBI) score is a new evidence-based approach to assess liver function. The ALBI score eliminates subjective variables, such as ascites and encephalopathy which are the requirements for the conventional C-P grading system. This study enrolled 654 patients to determine whether the ALBI score can predict the outcomes of postoperative solitary HCC patients within the Milan criteria and C-P A cirrhosis. Our results showed the ALBI score significantly influenced the overall survival and cumulative recurrence rates. Furthermore, the ALBI score was significantly related to the degree of liver cirrhosis and serum γ-glutamyl transpeptidase (GGT) concentration in solitary HCC cases within the Milan criteria and C-P A cirrhosis. Additionally, the combination of the ALBI score and serum GGT concentration contributed to the prognosis prediction in this cohort. In conclusion, we externally validated the ALBI grade as a novel biomarker to predict prognosis for solitary HCC within the Milan Criteria and C-P A cirrhosis.

Indexed as

Albumin-Bilirubin ScoreChild-Pugh AHCCMilan Criteria

Identifiers

PMID29151974
PMCPMC5688940
OpenAlexW2765114359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.